CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH From the pages of Clinical Advances in Hematology & Oncology comes this Q&A with Jennifer A. Woyach, MD, a Professor of Medicine in the Division of Hematology at the Ohio State University Comprehensive Cancer Center. Dr. Woyach provides extensive commentary on BTK, BCL2, and PI3K inhibitors, FCR usage, and the importance of clinical trials when treating patients with CLL.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
